Patient Outcomes

GLP-1 Success Stories

Real patient results with GLP-1 weight loss medications — representative of Phase III clinical trial data. Physician-supervised programs with dietary guidance and ongoing support.

16.6%
avg weight loss Wegovy® pill — OASIS 4
20.9%
avg weight loss Zepbound® — SURMOUNT-1
14.9%
avg weight loss Wegovy® injection — STEP-1
70%+
of prediabetic patients normalize blood glucose
Patient Experiences

What GLP-1 treatment looks like in practice

Representative patient experiences consistent with published Phase III clinical trial data. Individual results vary. All patients followed physician-supervised programs with reduced-calorie diets and increased physical activity.

S.M.
Sarah M.
Female, 42, Texas
38 lbs
weight lost
6 months
on treatment
Wegovy® injection

“I tried everything for years — WW, keto, intermittent fasting. At six months I had lost more weight than I had in the previous three years combined. The nausea was rough for the first month but completely manageable once my physician slowed my escalation pace.”

Key outcomes
38 lbs lost · Blood pressure normalized · Off BP medication
J.T.
James T.
Male, 55, Florida
51 lbs
weight lost
9 months
on treatment
Zepbound®

“My A1C dropped from 6.1 to 5.4 and my cardiologist reduced my blood pressure medication at the six-month visit. I didn’t just lose weight — my whole metabolic picture changed. My wife says she got her husband back.”

Key outcomes
51 lbs lost · A1C 6.1→5.4 · BP medication reduced
M.R.
Maria R.
Female, 38, California
29 lbs
weight lost
5 months
on treatment
Wegovy® pill

“I travel constantly for work and the injection was never realistic — no refrigeration, different time zones. The pill changed everything. I take it every morning before breakfast and it just works. No needles, no carrying a cooler.”

Key outcomes
29 lbs lost · No injection needed · Travel-friendly
D.K.
David K.
Male, 48, Georgia
44 lbs
weight lost
8 months
on treatment
Zepbound®

“Sleep apnea, hypertension, and my knees hurt every time I walked up stairs. Eight months later my sleep study is normal, I’m off one blood pressure medication, and I walked a 5K with my daughter last month.”

Key outcomes
44 lbs lost · Sleep apnea resolved · Off 1 BP medication
L.W.
Lisa W.
Female, 51, New York
33 lbs
weight lost
7 months
on treatment
Wegovy® injection

“Perimenopause made my weight completely impossible to manage for three years. Every approach I tried just stopped working. Wegovy was the first thing that actually worked with my hormonal situation rather than against it.”

Key outcomes
33 lbs lost · Improved metabolic markers · Better sleep
R.P.
Robert P.
Male, 44, Ohio
27 lbs
weight lost
5 months
on treatment
Wegovy® pill

“I was skeptical — the injectable had a longer track record. But my physician explained the OASIS 4 trials showed comparable results, and at $149/month versus $349 for the injection, the economics made the decision clear. Twenty-seven pounds in five months.”

Key outcomes
27 lbs lost · $149/month self-pay · No injection required
Clinical trial data

Patient experiences are representative of outcomes consistent with published Phase III data. Individual results vary based on adherence, diet, activity, and individual response.

Wegovy® pill (OASIS 4)
16.6%
mean weight loss, full adherence, 64 weeks
Zepbound® (SURMOUNT-1)
20.9%
mean weight loss at 72 weeks
Wegovy® injection (STEP-1)
14.9%
mean weight loss at 68 weeks
Ozempic® (SUSTAIN-6)
4.2%
mean weight loss, 104 weeks, T2D patients
Beyond the Scale

Cardiometabolic benefits patients experience

Weight loss is only part of the GLP-1 story. The cardiometabolic improvements documented in trials — and experienced by patients — are equally significant.

20%
CV event reduction
Wegovy® reduces major adverse cardiovascular events in patients with established heart disease (SELECT trial)
70%+
Prediabetes reversal
Patients with prediabetes normalize blood glucose with oral semaglutide in OASIS 4 trials
-7 pts
Blood pressure reduction
Average systolic blood pressure reduction at 12 months on semaglutide
50%
Sleep apnea improvement
Patients with OSA see significant improvement with GLP-1-associated weight loss
About These Results

Understanding patient outcomes

Transparent context for the results you see.

The stories above are representative patient experiences — composite accounts based on outcomes consistent with published clinical trial data. Names and identifying details are changed for privacy. The weight loss figures and comorbidity improvements cited reflect outcomes documented in Phase III clinical trials.
Individual GLP-1 response varies based on: baseline weight, dose achieved, dietary adherence, physical activity, starting metabolic health, medication adherence, and genetic factors affecting GLP-1 receptor sensitivity. The physician you're connected with will set realistic expectations for your specific profile.
Based on Phase III trial data, most patients achieve 10–20% body weight loss with full treatment adherence at 12 months. One in three patients on the highest-dose medications achieves 20% or greater weight loss. Patients who combine GLP-1 treatment with strong dietary habits and regular activity consistently achieve better outcomes.
Weight regain occurs in most patients who discontinue without a transition plan. Patients who build sustainable dietary patterns during treatment maintain significantly better long-term outcomes than those who relied solely on the medication. This is why nutrition coaching and ongoing care are central to the FirstCall program.

Related programs

All options available through Physicians on the FirstCall platform.

Qualification Quiz
Qualification Quiz
check your eligibility in 5 questions
GLP-1 Programs
GLP-1 Programs
view all weight loss options
Ongoing Care
Ongoing Care
continuous support through treatment

Start writing your own success story.

Free physician evaluation. Same-day access. All 50 states.